Millennium Management
ZNTL icon

Millennium Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Millennium Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30,000
Closed -$1.38M – 7595
2022
Q1 		$1.38M Buy
+30,000
New +$1.62M ﹤0.01% 4216

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Millennium Management's ZNTL Position: Q1 2026 in Review

Millennium Management increased its Zentalis Pharmaceuticals (ZNTL) stake by 92% in Q1 2026, buying an estimated $1.59M and bringing the position to 1,289,822 shares worth $3.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3455.

Millennium Management first reported a position in ZNTL in Q1 2021 and has held it in 18 quarters since. The position peaked at $8.97M in Q3 2023. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Millennium Management held 1,289,822 shares of Zentalis Pharmaceuticals worth $3.02M as of Q1 2026.
  • Millennium Management bought 616,693 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $1.59M.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3455 holding.
  • Millennium Management first reported a position in Zentalis Pharmaceuticals in Q1 2021 and has held it in 18 quarters since.
  • Millennium Management's Zentalis Pharmaceuticals position peaked at $8.97M in Q3 2023.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.